Efficacy of various antihypertensive agents as evaluated by indices of vascular stiffness in elderly hypertensive patients

Hypertension Research

Volumn 26, Issue 8, 2003, Pages 609-614

  Takami, Takeshi ^a   Shigemasa, Minori ^a  

^a Clinic Jinguumae   (Japan)

Author keywords

Angiotensin receptor blocker; Arterial stiffness; Brachial ankle pulse wave velocity; Hypertension in the elderly; Pulse pressure

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CILNIDIPINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NIFEDIPINE; TEMOCAPRIL; VALSARTAN;

AGED; ANTIHYPERTENSIVE ACTIVITY; ARTERIOSCLEROSIS; ARTERY COMPLIANCE; ARTICLE; BRACHIAL ANGIOGRAPHY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; LEG ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PULSE PRESSURE; PULSE WAVE; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANKLE; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; BRACHIAL ARTERY; CALCIUM CHANNEL BLOCKERS; DIHYDROPYRIDINES; FEMALE; HUMANS; HYPERTENSION; MALE; NIFEDIPINE; PULSATILE FLOW; RECEPTORS, ANGIOTENSIN; TETRAZOLES; THIAZEPINES; TREATMENT OUTCOME; VALINE;

EID: 0042327753     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.26.609     Document Type: Article

References (34)

1. Franklin SS, Khan SA, Wong ND, Larson MG, Levy D: Is pulse pressure useful in predicting risk for coronary heart disease?: the Framingham heart study. Circulation 1999; 100: 354-360.
2. Millar JA, Lever AF, Burke V: Pulse pressure as a risk factor for cardiovascular events in the MRC mild hypertension trial. J Hypertens 1999; 17: 1065-1072.
3. Blacher J, Staessen JA, Girerd X, et al: Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085-1089.
4. Mitchell GF, Moye LA, Braunwald E, et al: Sphygmomanometrically determined pulse pressure is a powerful independent predictor of recurrent events after myocardial infarction in patients with impaired left ventricular function. Circulation 1997; 96: 4254-4260.
5. Domanski MJ, Mitchell GF, Norman JE, Exner DV, Pitt B, Pfeffer MA: Independent prognostic information provided by sphygmomanometrically determined pulse pressure and mean arterial pressure in patients with left ventricular dysfunction. J Am Coll Cardiol 1999; 33: 951-958.
6. Ogihara T, Morimoto S, Okaishi K, et al: Questionnaire survey on the Japanese guidelines for treatment of hypertension in the elderly 1999 revised version. Hypertens Res 2002; 25: 69-75.
7. Saito I, Kawabe H, Tsujioka M, Hirose H, Shibata H: Trends in pharmacologic management of hypertension in Japan one year after the publication of the JSH 2000 guidelines. Hypertens Res 2002; 25: 175-178.
8. Amett DK, Evans GW, Riley WA: Arterial stiffness: a new cardiovascular risk factor? Am J Epidemiol 1994; 140: 669-682.
9. Lehmann ED: Clinical value of aortic pulse-wave velocity measurement. Lancet 1999; 354: 528-529.
10. Komai N, Ohishi M, Moriguchi A, et al: Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002; 25: 5-10.
11. Kubo T, Miyata M, Minagoe S, Setoyama S, Maruyama I, Tei C: A simple oscillometric technique for determining new indices of arterial distensibility. Hypertens Res 2002; 25: 351-358.
12. Blacher J, Asmar R, Djane S, London GM, Safar ME: Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33: 1111-1117.
13. Laurent S, Boutouyrie P, Asmar R, et al: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 2001; 37: 1236-1241.
14. Yamashina A, Tomiyama H, Takeda K, et al: Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 2002; 25: 359-364.
15. Sun K, Daimon M, Watanabe S, Komuro I, Masuda Y: The relation of pulse wave velocities measured by oscillometric and tonometric methods and clinical application studies. Jpn J Appl Physiol 2002; 32: 81-86.
16. Asmar R, Topouchian J, Pannier B, et al: Pulse wave velocity as endpoint in large-scale intervention trial: the Complior Study. J Hypertens 2001; 19: 813-818.
17. Iwatsubo H, Nagano M, Sakai T, et al: Converting enzyme inhibitor improves forearm reactive hyperemia in essential hypertension. Hypertension 1997; 29: 286-290.
18. Takata M, Ueno H, Hirai T, Oh-hashi S, Yasumoto K, Inoue H: Time course of the effects of temocapril on cardiovascular structure and function in patients with essential hypertension. J Cardiovasc Pharmacol 1999; 34: 561-566.
19. Mahmud A, Feely J: Reduction in arterial stiffness with angiotensin II antagonist is comparable with and additive to ACE inhibition. Am J Hypertens 2002; 15: 321-325.
20. Rehman A, Rahman ARA, Rasool AHG: Effect of angiotensin II on pulse wave velocity in humans is mediated through angiotensin II type 1 (AT1) receptors. J Hum Hypertens 2002; 16: 261-266.
21. Fujii S, Kameyama K, Hosono M, Hayashi Y, Kitamura K: Effect of cilnidipine, a novel dihydropyridine Ca-channel antagonist, on N-type Ca channel in rat dorsal root ganglion neurons. J Pharmacol Exp Ther 1997; 280: 1184-1191.
22. Uneyama H, Uchida H, Konda T, Yoshimoto R, Akaike N: Selectivity of dihydropiridines for cardiac L-type and sympathetic N-type Ca channels. Eur J Pharmacol 1999; 373: 93-100.
23. Sakata K, Shirotani M, Yoshida H, et al: Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 1999; 33: 1447-1452.
24. Wilkinson IB, McCallum H, Hupperetz PC, Thoor CJ, Cockcroft JR, Webb DJ: Changes in the derived central pressure waveform and pulse pressure in response to angiotensin II and noradrenaline in man. J Physiol (Lond) 2001; 530: 541-550.
25. Lajemi M, Labat C, Gautier S, et al: Angiotensin II type 1 receptor-153 A/G and 1166 A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001; 19: 407-413.
26. Benetos A, Levy BI, Lacolley P, Taillard F, Duriez M, Safar ME: Role of angiotensin II and bradykinin on aortic collagen following converting enzyme inhibition in spontaneously hypertensive rats. Arterioscler Thromb Vasc Biol 1997; 17: 3196-3201.
27. Safar ME: Antihypertensive effects of nitrates in chronic human hypertension. J Appl Cardiol 1990; 5: 69-81.
28. Wang H, Hu D, Sun N, Gong L, Zhang W: Effect of long-acting isosorbide-5-mononitrate administration on large artery distensibility in patients with essential hypertension. Hypertens Res 2001; 24: 311-314.
29. Komai N, Ohishi M, Moriguchi A, et al: Low-dose doxazosin improved aortic stiffness and endothelial dysfunction as measured by noninvasive evaluation. Hypertens Res 2002; 25: 5-10.
30. Siragy HM, Gasparo MD, Carey RM: Angiotensin type 2 receptor mediates valsartan-induced hypotension in conscious rats. Hypertension 2000; 35: 1074-1077.
31. Pieper GM, Siebeneich W: Temocapril, an angiotensin converting enzyme inhibitor, protects against diabetes-induced endothelial dysfunction. Eur J Pharmacol 2000; 403: 129-132.
32. Kobayashi N, Mori Y, Mita S, et al: Effects of cilnidipine on nitric oxide and endothelin-1 expression and extracellular signal-regulated kinase in hypertensive rats. Eur J Pharmacol 2001; 422: 149-157.
33. Fukuo K, Yang J, Yasuda O, et al: Nifedipine indirectly upregulates superoxide dismutase expression in cells via vascular smooth muscle cell-dependent pathways. Circulation 2002; 16: 357-361.
34. Albaladejo P, Bouaziz H, Duriez M, et al: Angiotensin-converting enzyme inhibition prevents the increase in aortic collagen in rats. Hypertension 1994; 23: 74-82